Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Towers At White Oak? High-Rises Could Help Solve Space Problems

Executive Summary

20- and 14-story office buildings among options to expand US FDA's White Oak headquarters.

You may also be interested in...



The Two Towers: US FDA's HQ Expansion Plans Include Office High-Rises, New Conference Center

Updated master plan for agency's White Oak headquarters is intended to meet needs of up to 18,000 employees.

FDA Planning For Possible Doubling Of HQ-Based Staff In 15 Years

Federal facilities agency will gauge impact of expanding US FDA staff located at the White Oak campus to about 18,000.

US FDA Hiring Initiative Aims To Get Scientific Staff More Involved In Recruitment

Commissioner Gottlieb's pilot program also creates dedicated recruitment staff that will work to fill prescription drug user fee-related openings, streamline the hiring process and improve employee retention.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS121572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel